October 2017

New Product - Rexulti

Rexulti (brexpiprazole) is a novel atypical antipsychotic agent with pharmacological activity as a serotonin-dopamine activity modulator. Brexpiprazole combines partial agonist activity at serotonergic 5HT_1A and at dopaminergic D₂ receptors with antagonist activity at serotonergic 5HT_2A receptors. Rexulti is indicated for the treatment of schizophrenia in adults. Rexulti is available as 1 mg, 2 mg, 3 mg and 4 mg tablets in pack sizes of 30.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.

Copyright © MIMS Australia Pty Ltd. All rights reserved.

MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629
info@mims.com.au
www.mims.com.au